Compare XBP & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBP | ATNM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 10998 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 42.0M |
| IPO Year | N/A | 2013 |
| Metric | XBP | ATNM |
|---|---|---|
| Price | $2.66 | $1.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $5.00 | $4.50 |
| AVG Volume (30 Days) | 18.3K | ★ 100.6K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.41 | $0.95 |
| 52 Week High | $8.55 | $1.95 |
| Indicator | XBP | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 55.06 |
| Support Level | $0.52 | $1.25 |
| Resistance Level | $8.46 | $1.38 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 49.00 | 52.00 |
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. By combining innovation with execution excellence, XBP Global helps businesses reimagine business process automation and enable digital transformation.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.